CRISPR Cure for High Cholesterol Begins Trials
25 July 2022 | New Zealand, United States
The first patient has been dosed with VERVE-101, in its heart-1 clinical trial. VERVE-101 is a novel, investigational gene editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol.
Login or Register You are not logged in. Please login or register with idtechex.com for more details about premium content from IDTechEx.